Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Clinical Trial

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

Benzinga

BREAKING: Cybin And Clinilabs Receive DEA License For First-In-Human Clinical Trial Of Psilocybin To Treat Depression

Cybin Inc. (NEO: CYBN) (NYSE: CYBN) and Clinilabs Drug Development Corporation (Clinilabs) announced that the U.S.

Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Miracle recovery saw Durham man bounce back from 'serious' stroke in time to meet his new baby a week later

Harrison Kingsley, 28, is on a clinical trial that could herald a huge breakthrough in stroke treatment

Chronicle Live

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug Application (NDA) for elacestrant for patients with ER+/HER2- advanced or metastatic breast cancer. The agency has granted Priority Review designation and assigned a target action date of February 17, 2023. Radius Health…

Benzinga

Urgent call for unclaimed frozen IVF eggs to go to life-saving clinical trials

Medical researchers are pushing for unclaimed IVF eggs to be donated for clinical research, rather than thrown away.

ABC News

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study evaluating Abecma (idecabtagene vicleucel) compared to standard combination regimens in adults with multiple myeloma that is relapsed and refractory. Bristol Myers shares traded in a range of $73.95 to $75.32 on a day volume…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ:MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. MediWound shares traded in a range of $1.6 to $1.76 on a day…

Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

Avalo Therapeutics (NASDAQ:AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II) ER). Avalo shares traded in a range of $3.5 to $3.91 on a day volume of 33.54 thousand shares,…

Benzinga

Bharat Biotech expects regulator’s nod for intranasal COVID-19 vaccine this month

Bharat Biotech completed clinical trials of the nasal vaccine with about 4,000 volunteers and there is no side effect or adverse reaction reported so far

The Hindu

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. Eledon shares traded in a range of $2.89 to $3.16 on a day volume of 31.27 thousand…

Benzinga

Brit, 39, who flew to US for cancer treatment dies in Texas after it failed to work

Cormac McLaughlin, from Co. Tyrone, passed away after flying to Texas for a clinical trial when he found out he was diagnosed with an aggressive brain tumour

Daily Mirror

Recap Of Friday's Biotech Catalysts - End of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193 in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Belfast Live

Family plea to get ill Co Tyrone man home after receiving cancer treatment in US

Cormac McLaughlin from Castlederg had travelled to Texas where he was accepted on a to a clinical trial to help save his life

The Independent UK

What is Paxlovid? Everything you need to know about Joe Biden’s antiviral Covid drug treatment

Late-stage clinical trial found nearly 90 per cent effectiveness from antiviral pill

Benzinga

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

AAP

NSW pitched as clinical trial hub in Seoul

With another potential COVID-19 wave on the way in Australia, NSW Premier Dominic Perrottet is pitching his state as a clinical trial hub to Korean scientists.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

InMed Provides An Update On Phase 2 Clinical Trial Investigating Cannabinol Cream For Epidermolysis Bullosa

InMed Pharmaceuticals Inc. (NASDAQ: INM) provided an update on its phase 2 clinical trial using investigational drug INM-755 cannabinol (“CBN”) cream for the treatment

ABC News

Meaghan thought psychedelic therapy could help her PTSD. Instead it was the start of a nightmare

When Meaghan did psychedelic therapy she was gagged and pinned down by her therapists. With psychedelics touted as a miracle cure, she wants her story known.

Benzinga

Recap Of Friday's Biotech Catalysts - End Of The Day Summary

Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and relatlimab) for treatment of patients with Unresectable or Metastatic Melanoma based on results from the Phase 2/3 RELATIVITY-047 trial. Bristol Myers shares traded in a range of $72.48 to $73.61 on a…

The Independent UK

Hallucinations are very much a part of my life – David Jensen

The DJ, nicknamed Kid, has been living with Parkinson’s disease for more than a decade.

Benzinga

Field Trip's Phase I Clinical Study Of Psilocybin Analog FT-104 Begins Dosing In Australia

Developer and provider of psychedelic therapies Field Trip Health Ltd. has announced the first successful dosing of a Phase 1 clinical trial on it's proprietary psychedelic molecule.

The Independent UK

What is Paxlovid? Everything you need to know about the antiviral Covid drug being taken by Joe Biden

Late-stage clinical trial found nearly 90 per cent effectiveness from antiviral pill

Benzinga

Incannex Approved To Commence Phase 1 Clinical Trial Of CBD Based Anti-Inflammatory Drug

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from the Bellberry Human Research Ethics Committee ('HREC') for a phase 1 clinical trial investigating its proprietary multi-use, anti-inflammatory drug IHL-675A

1 … 13 14 15 16

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.